05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
gene therapy products, namely, genetically modified cells for medical use for the treatment of dystrophic epidermolysis bullosa; pharmaceutical preparations and injectable biological preparations containing genetically modified materials for treatment of dystrophic epidermolysis bullosa; pharmaceutical preparations and therapeutic preparations for treatment of skin diseases, connective tissue diseases, arthritis and autoimmune diseases
2.
Dosage Unit Formulations Of Autologous Dermal Fibroblasts
Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×107 cells/mL. When injected into the nasolabial fold wrinkles (creases on the sides of the nose that extend to the corners of the mouth), the autologous fibroblasts are thought to increase the synthesis of extracellular matrix components, including collagen, reducing the severity of these wrinkles. Dosage and timing of administration have been demonstrated to be critical to achieving clinically significant outcomes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical or medical preparations for skin diseases,
connective tissue diseases, arthritis and autoimmune
diseases; therapeutic preparations for skin diseases,
connective tissue diseases, arthritis and autoimmune
diseases; therapeutic preparations for skin care, cosmetic
procedures, cell therapies and gene therapies.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research and development, namely, research and
development of pharmaceutical and medical preparations for
skin diseases, connective tissue diseases, arthritis and
autoimmune diseases; scientific research and development of
therapeutics and procedures for skin diseases, connective
tissue diseases, arthritis and autoimmune diseases;
scientific research and development of preparations and
therapeutics for skin care; scientific research and
development of cell therapies and gene therapies.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical or medical preparations for skin diseases,
connective tissue diseases, arthritis and autoimmune
diseases; therapeutic preparations for skin diseases,
connective tissue diseases, arthritis and autoimmune
diseases; therapeutic preparations for skin care, cosmetic
procedures, cell therapies and gene therapies.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research and development, namely, research and
development of pharmaceutical and medical preparations for
skin diseases, connective tissue diseases, arthritis and
autoimmune diseases; scientific research and development of
therapeutics and procedures for skin diseases, connective
tissue diseases, arthritis and autoimmune diseases;
scientific research and development of preparations and
therapeutics.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical and medical preparations for skin diseases, namely, fungal skin infections, viral skin infections and parasitic skin infections, and skin cancer, connective tissue diseases, arthritis and autoimmune diseases; therapeutic pharmaceutical preparations for skin diseases, namely, fungal skin infections, viral skin infections and parasitic skin infections, and skin cancer, connective tissue diseases, arthritis and autoimmune diseases; therapeutic preparations for cleansing the skin for medical skin care, cosmetic procedures, cell therapies and gene therapies.
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Scientific research and development, namely, research and development of pharmaceutical and medical preparations for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development of therapeutics and procedures in the field of pharmaceuticals for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development in the field of pharmaceutical preparations and therapeutic medicines for skin care; scientific research and development of cell therapies and gene therapies.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical and medical preparations for skin diseases, namely, fungal skin infections, viral skin infections and parasitic skin infections, and skin cancer, connective tissue diseases, arthritis and autoimmune diseases; therapeutic pharmaceutical preparations for skin diseases, namely, fungal skin infections, viral skin infections and parasitic skin infections, and skin cancer, connective tissue diseases, arthritis and autoimmune diseases; therapeutic preparations for cleansing the skin for medical skin care, cosmetic procedures, cell therapies and gene therapies.
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Scientific research and development, namely, research and development of pharmaceutical and medical preparations for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development of therapeutics and procedures in the field of pharmaceuticals for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development in the field of biologic therapeutic preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and medical preparations for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; therapeutic preparations for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; therapeutic preparations for skin care, cosmetic procedures, cell therapies and gene therapies
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research and development, namely, research and development of pharmaceutical and medical preparations for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development of therapeutics and procedures for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development of preparations and therapeutics for skin care; scientific research and development of cell therapies and gene therapies
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research and development, namely, research and development of pharmaceutical and medical preparations for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development of therapeutics and procedures for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development of preparations and therapeutics
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and medical preparations for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; therapeutic preparations for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; therapeutic preparations for skin care, cosmetic procedures, cell therapies and gene therapies
15.
COMPOSITIONS AND METHODS FOR TREATMENT OF TYPE VIII COLLAGEN DEFICIENCIES
The present invention relates to self-inactivating lentiviral vectors comprising the COL7A1 gene or a functional variant thereof and its use in a method for the treatment of Type VII collagen deficiency, such as dominant dystrophic epidermolysis and recessive dystrophic epidermolysis.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
17.
Methods for culturing minimally-passaged fibroblasts and uses thereof
The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical and / or medical preparations consisting of cell and gene therapies; medicated skin care and treatment preparations consisting of cell and gene therapies. Scientific research and development; research and development of regenerative cells for medical and scientific applications; research and development relating to medical, dental procedures and / or cosmetic procedures consisting of cell and gene therapies; cosmetic research and development consisting of cell and gene therapies.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical and/or medical preparations consisting of cell and gene therapies; medicated skin care and treatment preparations consisting of cell and gene therapies. Scientific research and development; research and development of regenerative cells for medical and scientific applications; research and development relating to medical, dental procedures and / or cosmetic procedures consisting of cell and gene therapies; cosmetic research and development consisting of cell and gene therapies.
21.
Treatment of vocal cords with autologous dermal fibroblast formulation
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
22.
Methods for culturing minimally-passaged fibroblasts and uses thereof
The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
23.
Dosage unit formulations of autologous dermal fibroblasts
7 cells/mL. When injected into the nasolabial fold wrinkles (creases on the sides of the nose that extend to the corners of the mouth), the autologous fibroblasts are thought to increase the synthesis of extracellular matrix components, including collagen, reducing the severity of these wrinkles. Dosage and timing of administration have been demonstrated to be critical to achieving clinically significant outcomes.
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
25.
Dosage unit formulations of autologous dermal fibroblasts
7 cells/mL. When injected into the nasolabial fold wrinkles (creases on the sides of the nose that extend to the corners of the mouth), the autologous fibroblasts are thought to increase the synthesis of extracellular matrix components, including collagen, reducing the severity of these wrinkles. Dosage and timing of administration have been demonstrated to be critical to achieving clinically significant outcomes.
Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0 x 107 cells/mL. When injected into the nasolabial fold wrinkles (creases on the sides of the nose that extend to the corners of the mouth), the autologous fibroblasts are thought to increase the synthesis of extracellular matrix components, including collagen, reducing the severity of these wrinkles. Dosage and timing of administration have been demonstrated to be critical to achieving clinically significant outcomes.
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.
